Rhaeos is a VC backed, clinical stage digital medical device company developing FlowSense, a platform technology and a noninvasive wireless, wearable skin patch that can assess and monitor flow peripherally throughout the body. The company is initially targeting hydrocephalus, a life threatening condition caused by an abnormal accumulation of cerebrospinal fluid. Implantable shunts, the gold standard treatment, often fail, leading to multiple trips to the emergency room and repeat surgeries. FlowSense is a thermal flow sensor that is mounted on a patient’s skin overlying the shunt to detect shunt flow in minutes, bedside, without capital equipment. Rhaeos has raised $8M in financing, received FDA breakthrough designation, published clinical data in Science and Nature family journals, and is on track for initial market entry in early 2022. Following the launch of the hydrocephalus devices, the company will launch wearables for other chronic medical conditions.Something looks off?